Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 8:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 83 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Arthritis Juvenile Idiopathic Clear all
Not listed No phase listed Observational Accepts healthy volunteers

PatientSpot Formerly Known as ArthritisPower

NCT03840928
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Jul 23, 2026, 8:13 PM EDT
Completed No phase listed Observational

Cost of Care for Juvenile Idiopathic Arthritis

NCT01469897
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Not listed
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
Omaha, Nebraska • Cleveland, Ohio • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Jul 23, 2026, 8:13 PM EDT
Completed Phase 4 Interventional Results available

A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)

NCT01544114
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis (JIA)
Interventions
VIMOVO 250/20, VIMOVO 375/20, VIMOVO 500/20
Drug
Lead sponsor
Amgen
Industry
Eligibility
12 Years to 16 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
17
States / cities
Little Rock, Arkansas • San Francisco, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Jul 23, 2026, 8:13 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Safety and Efficacy of Abatacept for Treating Chronic Cytopenia in Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Haploinsufficiency

NCT03733067
View directory record Official record
Conditions
CTLA4 Haploinsufficency, Chronic Cytopenia
Interventions
abatacept, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 3, 2023 · Synced Jul 23, 2026, 8:13 PM EDT
Completed Phase 3 Interventional Results available

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)

NCT00642460
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
tocilizumab [RoActemra/Actemra], Placebo, Non-steroidal anti-inflammatory drugs (NSAIDs), methotrexate, corticosteroids
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 17 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
13
States / cities
Little Rock, Arkansas • Los Angeles, California • Hartford, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2016 · Synced Jul 23, 2026, 8:13 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)

NCT03311854
View directory record Official record
Conditions
Macrophage Activation Syndrome, Lymphohistiocytosis, Hemophagocytic, Arthritis, Juvenile, Adult Onset Still Disease
Interventions
Emapalumab
Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
0 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Jul 23, 2026, 8:13 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)

NCT01455701
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Up to 24 Months
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
9
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2019 · Synced Jul 23, 2026, 8:13 PM EDT
Completed Phase 3 Interventional Results available

A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis

NCT00988221
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Tocilizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 17 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
10
States / cities
Hartford, Connecticut • Washington D.C., District of Columbia • Delray Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Jul 23, 2026, 8:13 PM EDT
Completed Phase 1 Interventional

Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis

NCT02165345
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 18 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
9
States / cities
Little Rock, Arkansas • Chicago, Illinois • Hackensack, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Jul 23, 2026, 8:13 PM EDT
Recruiting No phase listed Observational

The BRIDGE Pain Study

NCT07602595
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis (JIA), Fibromyalgia, Lupus, Scoliosis, Pectus Excavatum, Chronic Pain, Musculoskeletal Pain
Interventions
Not applicable- observational study
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
14 Years to 26 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 23, 2026, 8:13 PM EDT
Completed Phase 3 Interventional Results available

Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)

NCT03841357
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Abatacept Injection, Usual Care
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
2 Years to 16 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
19
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Jul 23, 2026, 8:13 PM EDT
Completed No phase listed Observational

Patient Centered Adaptive Treatment Strategies Using Bayesian Causal Inference

NCT02524340
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Year to 19 Years
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 22, 2019 · Synced Jul 23, 2026, 8:13 PM EDT
Recruiting Phase 3 Interventional

Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis

NCT06654882
View directory record Official record
Conditions
Polyarticular Course Juvenile Idiopathic Arthritis (JIA)
Interventions
TNFi (Tumor Necrosis Factor inhibitor) medication, Abatacept, Tocilizumab, Tofacitinib
Drug
Lead sponsor
Duke University
Other
Eligibility
2 Years to 17 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
4
States / cities
San Francisco, California • Gainesville, Florida • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jul 23, 2026, 8:13 PM EDT
Active, not recruiting No phase listed Observational

An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis

NCT01357668
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Up to 17 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2029
U.S. locations
3
States / cities
Little Rock, Arkansas • Princeton, New Jersey • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Jul 23, 2026, 8:13 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Pain in Juvenile Arthritis

NCT07217782
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Pressure pain thresholds (measured in kilopascal), Cold pain tolerance (duration in seconds)
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
9 Years to 17 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2035
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 23, 2026, 8:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Yoga Therapy for Adolescents With Juvenile Idiopathic Arthritis

NCT03286933
View directory record Official record
Conditions
Adolescent Juvenile Idiopathic Arthritis, Yoga Therapy
Interventions
yoga
Behavioral
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
14 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Jul 23, 2026, 8:13 PM EDT
Not yet recruiting Phase 4 Interventional

Adalimumab Dose Adjustment for Pediatric Uveitis Treatment Trial

NCT07699107
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis Associated Uveitis, Uveitis, Anterior
Interventions
Adalimumab/Biosimilar
Biological
Lead sponsor
Nisha Acharya
Other
Eligibility
2 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
9
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 23, 2026, 8:13 PM EDT
Terminated Phase 2 Interventional Results available

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

NCT05000216
View directory record Official record
Conditions
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
Interventions
Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
29
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jul 23, 2026, 8:13 PM EDT
Completed Phase 3 Interventional Results available

Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)

NCT03031782
View directory record Official record
Conditions
Juvenile Psoriatic Arthritis, Enthesitis-related Arthritis
Interventions
secukinumab, placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 17 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Los Angeles, California • Boise, Idaho • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2022 · Synced Jul 23, 2026, 8:13 PM EDT
Terminated Phase 2 Interventional Results available

Transcutaneous Cervical Vagus Nerve Stimulation (tcVNS) in JIA

NCT05710640
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis (JIA)
Interventions
Active tcVNS, Sham tcVNS
Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years to 18 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
San Francisco, California • Orlando, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Jul 23, 2026, 8:13 PM EDT
Completed Phase 4 Interventional Results available

A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects

NCT00807846
View directory record Official record
Conditions
Arthritis, Juvenile Rheumatoid
Interventions
Celecoxib, Naproxen
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
18
States / cities
Tucson, Arizona • Little Rock, Arkansas • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Jul 23, 2026, 8:13 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of Web-based Pain Self-management for Adolescents With Juvenile Idiopathic Arthritis

NCT01541917
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Web-based coping skills training, Online disease education
Behavioral
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
12 Years to 18 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
10
States / cities
San Francisco, California • Chicago, Illinois • Indianopolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Jul 23, 2026, 8:13 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD)

NCT03265132
View directory record Official record
Conditions
Still's Disease, Adult-Onset, Still's Disease, Juvenile-Onset
Interventions
anakinra, Placebo
Biological · Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
Not listed
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
36
States / cities
Birmingham, Alabama • Beverly Hills, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Jul 23, 2026, 8:13 PM EDT
Completed Phase 2 Interventional Results available

Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis

NCT00130637
View directory record Official record
Conditions
Anterior Uveitis, Arthritis, Juvenile Idiopathic, Iritis, Immunosuppression
Interventions
Daclizumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
6 Years to 18 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Jul 23, 2026, 8:13 PM EDT